Upfront Surgery in Triple-Negative Breast Cancer: Stage and Tumor Size Criteria

Introduction to Treatment Approaches

The American College of Surgeons and oncology experts recommend upfront surgery for triple-negative breast cancer tumors ≤2 cm with clinically negative axilla, while neoadjuvant chemotherapy is strongly preferred for tumors >2 cm or Stage II-III disease, regardless of surgical feasibility 1, 2, 3

For small tumors ≤2 cm with clinically negative nodes, upfront surgery is appropriate, though nearly half of experts still recommend neoadjuvant chemotherapy to assess treatment response and guide adjuvant decisions 2
Breast-conserving surgery with sentinel lymph node biopsy is the standard surgical approach for Stage I disease 2

Neoadjuvant chemotherapy is the preferred and standard approach for all Stage II or III TNBC before definitive surgery, regardless of whether optimal surgery is technically feasible upfront, as recommended by the European Society for Medical Oncology 1, 4
This recommendation applies to TNBC tumors >2 cm and/or with positive axilla, even when breast conservation is immediately feasible, according to the National Comprehensive Cancer Network 1
The rationale for neoadjuvant therapy includes tumor downstaging, assessment of pathologic complete response as a prognostic marker, and the opportunity to tailor post-surgical adjuvant therapy based on residual disease, as supported by the American Society of Clinical Oncology 4, 3

For TNBC with aggressive phenotype, tumor ≤2 cm and clinically node-negative, consider upfront surgery, though neoadjuvant therapy is still preferred by many experts, as suggested by the European Society for Medical Oncology 1, 2
Tumor >2 cm or clinically node-positive requires neoadjuvant chemotherapy mandatory before surgery, as recommended by the National Comprehensive Cancer Network 1, 3

For patients achieving satisfactory response to neoadjuvant therapy, breast-conserving surgery followed by mandatory radiation is preferred, according to the American Society of Clinical Oncology 1
Sentinel lymph node biopsy may be considered for patients with clinically positive nodes that become clinically negative after neoadjuvant treatment, as suggested by the Society of Surgical Oncology 2